Late stage gastric cancer patients with extra gained HER2 positivity by dual block assessment may not show compromised efficacy to trastuzumab treatment.

In conclusion, our study suggests that patients with extra gained HER2 positivity may not show compromised efficacy to trastuzumab treatment.
PMID: 31739285 [PubMed - as supplied by publisher]

Source: Aging - November 16, 2019 Category: Biomedical Science Authors: Xu C, Liu Y, Jiang D, Ge X, Huang J, Su J, Zhang X, Lu S, Ji Y, Hou J, Liu T, Hou Y Tags: Aging (Albany NY) Source Type: research